About us

15
+
Projects since 2019
30
m
Antibody secreting cells screened
1
in
2500
up to
1
in
5000
Positive event rate
Learn more about our approach

VERAXA Biotech specializes in ADC development combining cutting-edge solutions for targeted antibody discovery and bioconjugation. Through biochemical and technological innovation, we strive to transform the way antibodies and antibody-drug conjugates (ADCs) are created to develop more effective and safe therapies for patients.

With our transformative technologies, we can streamline and derisk early bioconjugate development. We have established a rich pipeline of proprietary ADCs and are collaborating with a number of partners to provide access to our unique research & development capabilities going from target to antibody to ADC.

Founded in Heidelberg, Germany, VERAXA is the fusion of two spin-offs from the research hub European Molecular Biology Laboratory (EMBL). Our company is born out of a deep passion for transformative scientific discoveries, and our experienced team is committed to using these discoveries to change the way we combat cancer.

Meet our team

Management

Christoph Antz
Ph.D., CEO, Co-Founder
View Bio
Close Bio
Christoph Antz
Ph.D., CEO, Co-Founder

Christoph is an experienced company executive and former venture capital manager in the fields of life sciences with special focus on drug development (small molecules and biologicals), diagnostics and instrumentation. Prior to VERAXA, he was Managing Director at Acousia Therapeutics (inner ear drug development) and Luxendo (light sheet microscopy).

Close bio
Torsten Bürgermeister
CFO
View Bio
Close Bio
Torsten Bürgermeister
CFO

Torsten has more than 20 years of professional and management experience within the fields of Finance and Business Development in global life science and tech companies such as Molecular Health, BASF Pharma, Techem Energy Services and Colt Telecom. He holds a Diploma in Business Administration from DHBW in Mannheim.

Close bio
Lars Hufnagel
Ph.D., CSO
View Bio
Close Bio
Lars Hufnagel
Ph.D., CSO

Lars has more than 15 years of experience in life sciences sector with a strong focus on integrating technologies from high precision instrumentation, software, photonics and biology. Prior to joining Veraxa he was General Manager and Vice President of Luxendo a Bruker company. Lars received his Ph.D. from the Max Planck Institute for Dynamics and Self Organization in Göttingen and has been Group Leader at EMBL Heidelberg and co-founded several companies in the biotechnology field.

Close bio
Heinz Schwer
Ph.D., MBA, CBO
View Bio
Close Bio
Heinz Schwer
Ph.D., MBA, CBO

Heinz is a successful entrepreneur in biotech industry. He currently serves EMBL Ventures as General Partner focusing on venture building in life science. Prior to that, Heinz was CEO of various biotech companies in Austria, The Netherlands and Germany of which all were acquired by large pharma or biotech companies. Heinz studied Chemistry in Regensburg and earned his PhD in Clinical Chemistry. He was postdoc at Harvard Medical School, USA and holds an MBA from Henley Business School, UK.

Close bio

Board of directors

Oliver Baumann
Acting Chairman of the Board
View Bio
Oliver Baumann
Acting Chairman of the Board

Oliver is a passionate entrepreneur and has more than 17 years of experience in investment banking, capital market strategies and life science. From 2003 to 2019, he held various positions at Credit Suisse and Sloan Asset Management Capital, where he focused on alternative investments, research in the biotech and medical technology sectors, and institutional clients. In addition, he holds various active board memberships.

Close bio
Jürgen Bauer
Ph.D., Board Member
View Bio
Jürgen Bauer
Ph.D., Board Member

Jürgen has more than 22 years of experience in successful business development and technology transfer. He is Deputy Managing Director and Head of Business Development at EMBLEM Technology Transfer GmbH, the commercial arm of the European Molecular Biology Laboratory (EMBL). Jürgen is a graduate of Johann Wolfgang Goethe University in Frankfurt (Biology) and holds a Ph.D. in Molecular Biology.

Close bio
David L. Deck
Board Member
View Bio
David L. Deck
Board Member

David is a deeply experienced entrepreneur in biotech with over 28 years of experience in company development and financing. David is focused on the life sciences industry and realized several successful exits in the area of biotech and Medtech up to date.

Close bio

Associated experts

Alexander S. Hauser
Ph.D.
View Bio
Alexander S. Hauser
Ph.D.

Alexander graduated from the University of Copenhagen with a strong background in G protein-coupled receptors focusing on the discovery of endogenous ligands and personalized medicine.

Close bio
Prof. Edward A. Lemke
Ph.D., Co-Founder & Scientific Advisor
View Bio
Prof. Edward A. Lemke
Ph.D., Co-Founder & Scientific Advisor

Edward is a Professor and Chair for synthetic biophysics in the Departments of Biology and Chemistry at the Johannes Gutenberg University Mainz. He is also an Adjunct Director at the Institute for Molecular Biology, Mainz.

Close bio
Prof. Dr. Matthias Miederer
M.D.
View Bio
Prof. Dr. Matthias Miederer
M.D.

Matthias is a professor and chair for department of Translational Imaging in Oncology at National Center for Tumor Diseases (NCT/UCC) Dresden, Germany with strong background in clinical oncology and basic science. He graduated from Technical University Munich and has a translational research focus on immune oncology.

Close bio
Prof. Hans-Georg Rammensee
Ph.D.
View Bio
Prof. Hans-Georg Rammensee
Ph.D.

Hans-Georg was appointed Chair of the Department of Immunology at the University of Tübingen in 1996, after spending three years as Head of the Tumor-Virus-Immunology Section of the German Cancer Research Center (DKFZ) in Heidelberg. He is co-founder of Immatics AG, Curevac AG and Synimmune GmbH.

Close bio
Michael Ruppert
Ph.D., MBA
View Bio
Michael Ruppert
Ph.D., MBA

Michael has 20 years experience in international business development in pharma, biotech, and medical device companies, and a long-standing track record as a seasoned deal-maker in the life science industry. He studied biology and holds a PhD in tumor immunology from the German Cancer Research Center in Heidelberg. He also received an MBA from Henley Management College, UK and currently serves as Director of International Business Development at Prestige Biopharma.

Close bio

Investors

VERAXA is a privately held company. Main shareholder is the Swiss company Xlife Sciences AG. Other shareholders are the European Molecular Biology Laboratory (EMBL) and its technology transfer arm EMBL Technology Transfer GmbH (EMBLEM), private investors, founders and management.

Join our team

We are your partner from target to antibody to ADC. Our unique antibody screening platform and proprietary ADC technology enable us to help you create the best targeted biotherapeutics for your application.

With partnership models tailored to your needs, we can join you at any step of your development journey, whether you are starting out with a target or are looking for a bioconjugation partner.

Careers